Fulgent Genetics beats Q3 revenue estimates, raises outlook

Fulgent Genetics

07/11/2025 12:12

Overview

Fulgent Q3 revenue grows 17% yr/yr, beating analyst expectations

Company raises full-year 2025 revenue guidance to $325 mln

Non-GAAP income for Q3 at $4.5 mln, despite GAAP loss

Outlook

Fulgent raises full-year 2025 revenue guidance to $325 mln

Company expects full-year 2025 GAAP loss of $1.70 per share

Fulgent anticipates $800 mln in cash and investments by year-end

Result Drivers

LAB SERVICES GROWTH - Co cites strong momentum in its laboratory services business as a key driver of Q3 revenue growth

THERAPEUTIC DEVELOPMENT - Progress in clinical trials, especially for FID-007, contributed to results, per CEO Ming Hsieh

GUIDANCE RAISED - Co raises full-year 2025 revenue and EPS guidance, reflecting confidence in strategic execution, per CFO Paul Kim

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$84.07 mln
$81.40 mln (3 Analysts)
Q3 EPS
-$0.21
Q3 Adjusted EBITDA
Beat
$700,000
-$6.05 mln (3 Analysts)
Q3 Pretax Profit
Miss
-$7.51 mln
-$7.24 mln (2 Analysts)
Q3 Gross Profit
$35.51 mln
Q3 Operating Expenses
$50.86 mln
Q3 Operating Income
-$15.35 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Fulgent Genetics Inc is $25.00, about 10.8% above its November 6 closing price of $22.31

Press Release: ID:nBw97mkL2a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)